CL2023003137A1 - Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras - Google Patents
Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nrasInfo
- Publication number
- CL2023003137A1 CL2023003137A1 CL2023003137A CL2023003137A CL2023003137A1 CL 2023003137 A1 CL2023003137 A1 CL 2023003137A1 CL 2023003137 A CL2023003137 A CL 2023003137A CL 2023003137 A CL2023003137 A CL 2023003137A CL 2023003137 A1 CL2023003137 A1 CL 2023003137A1
- Authority
- CL
- Chile
- Prior art keywords
- hras
- nras
- cyclic compound
- compound containing
- inhibitory action
- Prior art date
Links
- 150000001923 cyclic compounds Chemical class 0.000 title abstract 4
- 101150117869 Hras gene Proteins 0.000 title 1
- 101150073096 NRAS gene Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 108010038807 Oligopeptides Chemical class 0.000 abstract 3
- 102000015636 Oligopeptides Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021079012 | 2021-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003137A1 true CL2023003137A1 (es) | 2024-06-14 |
Family
ID=83932768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003137A CL2023003137A1 (es) | 2021-05-07 | 2023-10-20 | Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240158446A1 (https=) |
| EP (1) | EP4309741A4 (https=) |
| JP (1) | JPWO2022234853A1 (https=) |
| KR (1) | KR20240005777A (https=) |
| CN (1) | CN117279933A (https=) |
| AR (1) | AR125796A1 (https=) |
| AU (1) | AU2022268781A1 (https=) |
| BR (1) | BR112023022755A2 (https=) |
| CA (1) | CA3218182A1 (https=) |
| CL (1) | CL2023003137A1 (https=) |
| CO (1) | CO2023014807A2 (https=) |
| CR (1) | CR20230572A (https=) |
| IL (1) | IL307605A (https=) |
| MX (1) | MX2023013139A (https=) |
| PE (1) | PE20250071A1 (https=) |
| TW (1) | TW202309063A (https=) |
| WO (1) | WO2022234853A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202446781A (zh) | 2011-12-28 | 2024-12-01 | 日商中外製藥股份有限公司 | 胜肽化合物之製造方法 |
| EP4166664A1 (en) | 2015-03-13 | 2023-04-19 | Chugai Seiyaku Kabushiki Kaisha | Modified aminoacyl-trna synthetase and use thereof |
| JP7187323B2 (ja) | 2017-01-31 | 2022-12-12 | 中外製薬株式会社 | 無細胞翻訳系におけるペプチドの合成方法 |
| KR20250007021A (ko) | 2017-06-09 | 2025-01-13 | 추가이 세이야쿠 가부시키가이샤 | N-치환 아미노산을 포함하는 펩타이드의 합성 방법 |
| EP3878836B1 (en) | 2018-11-07 | 2025-07-23 | Chugai Seiyaku Kabushiki Kaisha | O-substituted serine derivative production method |
| EP4056580A4 (en) | 2019-11-07 | 2023-12-06 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PRODUCING A PEPTIDE COMPOUND COMPRISING A STERICALLY HINDERED AMINO ACID |
| BR112022007535A2 (pt) | 2019-11-07 | 2022-07-12 | Chugai Pharmaceutical Co Ltd | Composto peptídico cíclico tendo ação inibitória de kras |
| US12312379B2 (en) | 2021-05-07 | 2025-05-27 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing cyclic compounds comprising N-substituted amino acid residues |
| JP7823181B2 (ja) * | 2022-05-06 | 2026-03-03 | 中外製薬株式会社 | Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物 |
| CN115385867A (zh) * | 2022-09-19 | 2022-11-25 | 安徽普利药业有限公司 | 一种氨基酸及其类似物的成环反应与开环方法 |
| TW202430537A (zh) * | 2022-10-20 | 2024-08-01 | 日商中外製藥股份有限公司 | 環狀胜肽的結晶的製造方法 |
| EP4603105A1 (en) * | 2022-11-09 | 2025-08-20 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing cyclic compound having selective kras inhibitory effect against hras and nras |
| CN120659773A (zh) * | 2022-11-09 | 2025-09-16 | 锐新医药公司 | 化合物、复合物以及其制备方法和用途 |
| WO2024101386A1 (ja) * | 2022-11-09 | 2024-05-16 | 中外製薬株式会社 | Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物 |
| WO2024195801A1 (ja) | 2023-03-20 | 2024-09-26 | 中外製薬株式会社 | 環状ペプチドの共結晶の製造方法 |
| TW202506168A (zh) | 2023-04-19 | 2025-02-16 | 日商中外製藥股份有限公司 | 包含環狀胜肽化合物及界面活性劑之組合物 |
| CN120936619A (zh) | 2023-04-20 | 2025-11-11 | 中外制药株式会社 | 用于生产环肽化合物的方法 |
| CN116655766B (zh) * | 2023-04-23 | 2023-12-12 | 山东第一医科大学(山东省医学科学院) | 一种订书肽及其制备方法和应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025162428A1 (en) * | 2024-01-29 | 2025-08-07 | Syneron Technology Co. Ltd. | Cyclic peptide compounds and compositions as ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN118324664B (zh) * | 2024-03-14 | 2026-04-07 | 四川鸿日医药科技有限公司 | 一种丝氨酸衍生物的制备方法 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026004834A1 (ja) * | 2024-06-25 | 2026-01-02 | 中外製薬株式会社 | 固体分散体、及びそれを含む組成物 |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026009920A1 (ja) * | 2024-07-03 | 2026-01-08 | 中外製薬株式会社 | 環状ペプチドの精製法及び製造法 |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2586411T3 (es) | 2011-03-04 | 2016-10-14 | New York University | Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras |
| TW202446781A (zh) | 2011-12-28 | 2024-12-01 | 日商中外製藥股份有限公司 | 胜肽化合物之製造方法 |
| WO2015179438A1 (en) * | 2014-05-20 | 2015-11-26 | Ohio State Innovation Foundation | Small molecule rac or rho inhibitors |
| US10954287B2 (en) * | 2016-04-15 | 2021-03-23 | Ra Pharmaceuticals, Inc. | Ras binding peptides and methods of use |
| CN110869544B (zh) | 2017-06-09 | 2024-03-08 | 中外制药株式会社 | 膜透过性高的环状肽化合物及包含其的文库 |
| KR20250007021A (ko) * | 2017-06-09 | 2025-01-13 | 추가이 세이야쿠 가부시키가이샤 | N-치환 아미노산을 포함하는 펩타이드의 합성 방법 |
| WO2020122182A1 (ja) * | 2018-12-12 | 2020-06-18 | 中外製薬株式会社 | 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法 |
| BR112022007535A2 (pt) * | 2019-11-07 | 2022-07-12 | Chugai Pharmaceutical Co Ltd | Composto peptídico cíclico tendo ação inibitória de kras |
-
2022
- 2022-05-06 KR KR1020237040757A patent/KR20240005777A/ko active Pending
- 2022-05-06 IL IL307605A patent/IL307605A/en unknown
- 2022-05-06 TW TW111117092A patent/TW202309063A/zh unknown
- 2022-05-06 AU AU2022268781A patent/AU2022268781A1/en active Pending
- 2022-05-06 CN CN202280032929.5A patent/CN117279933A/zh active Pending
- 2022-05-06 JP JP2023518700A patent/JPWO2022234853A1/ja active Pending
- 2022-05-06 MX MX2023013139A patent/MX2023013139A/es unknown
- 2022-05-06 EP EP22798957.1A patent/EP4309741A4/en active Pending
- 2022-05-06 CR CR20230572A patent/CR20230572A/es unknown
- 2022-05-06 BR BR112023022755A patent/BR112023022755A2/pt unknown
- 2022-05-06 US US18/289,592 patent/US20240158446A1/en active Pending
- 2022-05-06 WO PCT/JP2022/019544 patent/WO2022234853A1/ja not_active Ceased
- 2022-05-06 AR ARP220101203A patent/AR125796A1/es unknown
- 2022-05-06 CA CA3218182A patent/CA3218182A1/en active Pending
- 2022-05-06 PE PE2023002874A patent/PE20250071A1/es unknown
-
2023
- 2023-10-20 CL CL2023003137A patent/CL2023003137A1/es unknown
- 2023-10-31 CO CONC2023/0014807A patent/CO2023014807A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL307605A (en) | 2023-12-01 |
| PE20250071A1 (es) | 2025-01-13 |
| CR20230572A (es) | 2024-01-25 |
| CA3218182A1 (en) | 2022-11-10 |
| MX2023013139A (es) | 2023-11-28 |
| AR125796A1 (es) | 2023-08-16 |
| TW202309063A (zh) | 2023-03-01 |
| JPWO2022234853A1 (https=) | 2022-11-10 |
| CN117279933A (zh) | 2023-12-22 |
| US20240158446A1 (en) | 2024-05-16 |
| EP4309741A1 (en) | 2024-01-24 |
| WO2022234853A1 (ja) | 2022-11-10 |
| KR20240005777A (ko) | 2024-01-12 |
| EP4309741A4 (en) | 2025-05-14 |
| BR112023022755A2 (pt) | 2024-01-02 |
| CO2023014807A2 (es) | 2023-11-20 |
| AU2022268781A1 (en) | 2023-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003137A1 (es) | Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras | |
| CO2024016293A2 (es) | Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras | |
| UY38057A (es) | Inhibidores de sarcómero cardíaco | |
| CL2024000373A1 (es) | Compuesto inductor de la degradación de plk1 novedoso | |
| CL2021000737A1 (es) | Fabricación de compuestos y composiciones para inhibir la actividad de shp2 | |
| CO2026002343A2 (es) | Inhibidores de pi3k | |
| MX2024002885A (es) | Inhibidor de la proteasa 3clpro. | |
| CL2023002616A1 (es) | Inhibidores del sarcómero cardíaco | |
| AR129946A1 (es) | Inhibidores de cbl-b y métodos de uso de los mismos | |
| AR078318A1 (es) | Compuestos carbonatos de anti-biopelicula para su uso en composiciones de cuidado oral | |
| CL2025001654A1 (es) | Compuestos novedosos como moduladores de la inhibición de nlrp3 | |
| CO2024003094A2 (es) | Compuesto imidazocíclico y aplicación del mismo | |
| DOP2025000116A (es) | Inhibidores de proteasas para tratar o prevenir la infección por coronavirus | |
| CO2024011857A2 (es) | Compuestos de uracilo n3-sustituidos como inhibidores de trpa1 | |
| ECSP088319A (es) | Síntesis de inhibidores de renina que involucra una reacción de cicloadición | |
| AR131116A1 (es) | Compuestos moduladores de nmda negativos y métodos de uso de estos | |
| CL2022002106A1 (es) | Moduladores de nampt. | |
| AR128100A1 (es) | Compuestos para el tratamiento de la pérdida del cabello | |
| MX2023013179A (es) | Metodos para elaborar un modulador de hemoglobina. | |
| CL2019002795A1 (es) | Proceso para preparar 2-exo-(2-metilbenciloxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano. | |
| AR129212A1 (es) | Compuestos piridona como inhibidores de trpa1 | |
| AR030373A1 (es) | Profarmacos para el tratamiento de enfermedades relacionadas con el receptor del nmda | |
| AR029855A1 (es) | Formas de sal de un inhibidor de la proteasa del hiv | |
| EA202192051A1 (ru) | Селективный ингибитор протеин-аргинин-метилтрансферазы 5 (prmt5) | |
| CO2025015375A2 (es) | Inhibidores de erbb2 |